Trials / Recruiting
RecruitingNCT06857955
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
A Randomized, Double-blind, Placebo-controlled, Multicenter, 12 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 380 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Detailed description
Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of QCZ484 with mild to moderate hypertension (HTN). Multiple doses of QCZ484 will be tested against placebo, administered as subcutaneous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Saline | 0.9% sodium chloride saline solution |
| DRUG | QCZ484 | Solution of Injection |
Timeline
- Start date
- 2025-03-26
- Primary completion
- 2027-01-29
- Completion
- 2028-04-05
- First posted
- 2025-03-05
- Last updated
- 2026-04-01
Locations
83 sites across 3 countries: United States, Japan, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06857955. Inclusion in this directory is not an endorsement.